



Discarded Drug Refund CY 2023 Updated Refund Quarters and CY 2024 New Refund Quarters

Generally, when a separately payable drug from a single-dose container or single-use package is administered to an individual enrolled in Medicare Part B, Medicare pays the provider or facility for both administered and discarded amounts of the drug, up to the labeled amount of the product. Section 90004 of the Infrastructure Investment and Jobs Act ([Pub. L. 117-58](#), November 15, 2021) amended section 1847A of the Social Security Act (the Act) by adding provisions that require manufacturers to provide a refund to CMS for certain discarded amounts from a single-dose container or single-use package drug. Generally, the refund amount is the amount of discarded drug that exceeds an applicable percentage, which is required to be at least 10 percent, of total charges for the drug in a given calendar quarter. For specific calculations for new refund quarters and updated refund quarters, refer to 42 CFR 414.940(c). For more information about the applicable percentage, refer to 42 CFR 414.940(d).

CMS sent discarded drug refund reports for CY 2023 “updated refund quarters” and CY 2024 “new refund quarters” (as defined at § 414.902) in September of 2025. Below are the billing and payment codes for which a manufacturer (or manufacturers) paid a refund, and the combined amount of refund paid for the four updated refund quarters in 2023 and four new refund quarters in 2024. These funds were deposited into the Supplementary Medical Insurance (SMI) trust fund, as required by law. Total refunds amount to **over \$173 million**.

Billing and Payment Code	Code Description	Combined Refund Amount Due for CY 2023 Updated Refund Quarters and CY 2024 New Refund Quarters
C9101	INJECTION, OLICERIDINE, 0.1 MG	\$178.06
C9482	INJECTION, SOTALOL HYDROCHLORIDE, 1 MG	\$119,613.75
J0122	INJECTION, ERAVACYCLINE, 1 MG	\$2,917.91
J0208	INJECTION, SODIUM THIOSULFATE (PEDMARK), 100 MG	\$8,485.46
J0485	INJECTION, BELATACEPT, 1 MG	\$7,747,377.55
J0565	INJECTION, BEZLOTOXUMAB, 10 MG	\$1,211,058.02
J0585	INJECTION, ONABOTULINUMTOXINA, 1 UNIT	\$6,707,936.25
J0587	INJECTION, RIMABOTULINUMTOXINB, 100 UNITS	\$29,768.19
J0606	INJECTION, ETELCALCETIDE, 0.1 MG	\$168.53
J0642	INJECTION, LEVOLEUCOVORIN (KHAPZORY), 0.5 MG	\$29,682.97
J0742	INJECTION, IMIPENEM 4 MG, CILASTATIN 4 MG AND RELEBACTAM 2 MG	\$65.74
J0893	INJECTION, DECITABINE (SUN PHARMA) NOT THERAPEUTICALLY EQUIVALENT TO J0894, 1 MG	\$46.75
J1448	INJECTION, TRILACICLIB, 1MG	\$2,839,049.45
J1921	INJECTION, LABETALOL HYDROCHLORIDE (HIKMA), NOT THERAPEUTICALLY EQUIVALENT TO J1920, 5 MG	\$1,749.96
J2372	INJECTION, PHENYLEPHRINE HYDROCHLORIDE (BIORPHEN), 20 MICROGRAMS	\$321.85
J2425	INJECTION, PALIFERMIN, 50 MICROGRAMS	\$8,198.69

Billing and Payment Code	Code Description	Combined Refund Amount Due for CY 2023 Updated Refund Quarters and CY 2024 New Refund Quarters
J2599	INJECTION, VASOPRESSIN (AMERICAN REGENT) NOT THERAPEUTICALLY EQUIVALENT TO J2598, 1 UNIT	\$51.99
J2786	INJECTION, RESLIZUMAB, 1 MG	\$4,843.08
J2796	INJECTION, ROMIPLOSTIM, 10 MICROGRAMS	\$11,250,002.43
J3095	INJECTION, TELAVANCIN, 10 MG	\$4,054.56
J3101	INJECTION, TENECTEPLASE, 1 MG	\$12,733,487.88
J3241	INJECTION, TEPROTUMUMAB-TRBW, 10 MG	\$7,747,303.40
J3396	INJECTION, VERTEPORFIN, 0.1 MG	\$132,421.93
J7665	MANNITOL, ADMINISTERED THROUGH AN INHALER, 5 MG	\$80.80
J9021	INJECTION, ASPARAGINASE, RECOMBINANT, (RYLAZE), 0.1 MG	\$4,733.64
J9042	INJECTION, BRENTUXIMAB VEDOTIN, 1 MG	\$6,923,583.42
J9043	INJECTION, CABAZITAXEL, 1 MG	\$28,220,040.28
J9046	INJECTION, BORTEZOMIB (DR. REDDY'S), NOT THERAPEUTICALLY EQUIVALENT TO J9041, 0.1 MG	\$98,053.25
J9048	INJECTION, BORTEZOMIB (FRESENIUS KABI), NOT THERAPEUTICALLY EQUIVALENT TO J9041, 0.1 MG	\$5,561.74
J9071	INJECTION, CYCLOPHOSPHAMIDE (AUROMEDICS), 5 MG	\$19,063.81
J9153	INJECTION, LIPOSOMAL, 1 MG DAUNORUBICIN AND 2.27 MG CYTARABINE	\$288,491.06
J9178	INJECTION, EPIRUBICIN HCL, 2 MG	\$865.28
J9179	INJECTION, ERIBULIN MESYLATE, 0.1 MG	\$327,592.45
J9198	INJECTION, GEMCITABINE HYDROCHLORIDE, (INFUGEM), 100 MG	\$2,196.50
J9205	INJECTION, IRINOTECAN LIPOSOME, 1 MG	\$3,389,199.48
J9223	INJECTION, LURBINECTEDIN, 0.1 MG	\$17,205,479.08
J9228	INJECTION, IPILIMUMAB, 1 MG	\$16,903,233.18
J9229	INJECTION, INOTUZUMAB OZOGAMICIN, 0.1 MG	\$2,707,625.20
J9264	INJECTION, PACLITAXEL PROTEIN-BOUND PARTICLES, 1 MG	\$4,170,320.02
J9269	INJECTION, TAGRAXOFUSP-ERZS, 10 MICROGRAMS	\$540,904.44
J9273	INJECTION, TISOTUMAB VEDOTIN-TFTV, 1 MG	\$90,436.75
J9281	MITOMYCIN PYELOALYCEAL INSTILLATION, 1 MG	\$3,453,006.87
J9307	INJECTION, PRALATREXATE, 1 MG	\$1,690,981.02
J9314	INJECTION, PEMETREXED (TEVA), NOT THERAPEUTICALLY EQUIVALENT TO J9305, 10 MG	\$176.44
J9328	INJECTION, TEMOZOLOMIDE, 1 MG	\$4,055.30
J9332	INJECTION, EFGARTIGIMOD ALFA-FCAB, 2MG	\$11,129,700.03
J9352	INJECTION, TRABECTEDIN, 0.1 MG	\$567,075.66
J9355	INJECTION, TRASTUZUMAB, EXCLUDES BIOSIMILAR, 10 MG	\$158,741.76
J9359	INJECTION, LONCASTUXIMAB TESIRINE-LPYL, 0.075 MG	\$7,178,227.80



Billing and Payment Code	Code Description	Combined Refund Amount Due for CY 2023 Updated Refund Quarters and CY 2024 New Refund Quarters
J9380	INJECTION, TECLISTAMAB-CQYV, 0.5 MG	\$17,347,970.14
J9381	INJECTION, TEPLIZUMAB-MZWV, 5 MCG	\$53,163.86
J9400	INJECTION, ZIV-AFLIBERCEPT, 1 MG	\$1,677.15
	TOTAL	\$173,061,020.81